Table 1.
Clinico-pathological characteristics of the patients (n = 8703)
| Characteristics | Number of patients, or median (range) |
Percentage of the study population |
|---|---|---|
| Age, years | ||
| median (range) | 53.7 (21.8–90.9) | NA |
| Size of tumor | ||
| T1 | 4042 | 46 |
| T2 | 3416 | 39 |
| T3–T4 | 1074 | 12 |
| missing data | 171 | 2 |
| Nodal status | ||
| N0 | 4593 | 53 |
| N1 | 3052 | 35 |
| N2 | 575 | 7 |
| N3 | 219 | 3 |
| missing data | 264 | 3 |
| SBR grade | ||
| I | 689 | 8 |
| II | 4034 | 46 |
| III | 3730 | 43 |
| missing data | 250 | 3 |
| Inflammatory breast cancer | ||
| yes | 317 | 4 |
| no | 8201 | 94 |
| missing data | 185 | 2 |
| Laterality | ||
| right | 4197 | 48 |
| left | 4347 | 50 |
| bilateral | 76 | 1 |
| missing data | 83 | 1 |
| Estrogen receptor status | ||
| negative | 2468 | 28 |
| positive | 6191 | 71 |
| missing data | 44 | 0.5 |
| Progesterone receptor status | ||
| negative | 3717 | 43 |
| positive | 4908 | 56 |
| missing data | 78 | 1 |
| HER2 status | ||
| negative | 5504 | 63 |
| positive | 3199 | 37 |
| Breast cancer subtypes | ||
| triple-negative breast cancer | 1115 | 13 |
| luminal breast cancer | 4355 | 50 |
| HER2-positive breast cancer | 3199 | 37 |
| missing data | 34 | 0.4 |
| Outcomes | ||
| recurrences | 1025 | 12 |
| deaths | 423 | 5 |
| - related to breast cancer | 359 | 4 |
| - unrelated to breast cancer | 64 | 0.7 |
SBR Scarff-Bloom-Richardson, HER2 human epidermal growth factor receptor 2, NA not applicable